On Monday, Arbutus Biopharma Corp (NASDAQ: ABUS) was -2.56% drop from the session before settling in for the closing price of $3.51. A 52-week range for ABUS has been $1.79 – $4.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 55.33% over the last five years. When this article was written, the company’s average yearly earnings per share was at 11.82%. With a float of $147.22 million, this company’s outstanding shares have now reached $169.87 million.
The firm has a total of 73 workers. Let’s measure their productivity. In terms of profitability, gross margin is 84.13%, operating margin of -1223.89%, and the pretax margin is -1137.64%.
Arbutus Biopharma Corp (ABUS) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arbutus Biopharma Corp stocks. The insider ownership of Arbutus Biopharma Corp is 22.31%, while institutional ownership is 53.46%. The most recent insider transaction that took place on Aug 14 ’24, was worth 32,637. In this transaction Director of this company sold 8,846 shares at a rate of $3.69, taking the stock ownership to the 46,069 shares. Before that another transaction happened on Feb 02 ’24, when Company’s Chief Medical Officer sold 4,358 for $2.31, making the entire transaction worth $10,078. This insider now owns 125,542 shares in total.
Arbutus Biopharma Corp (ABUS) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.16 earnings per share (EPS) during the time that was better than consensus figure (set at -0.16) by -0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 11.82% per share during the next fiscal year.
Arbutus Biopharma Corp (NASDAQ: ABUS) Trading Performance Indicators
You can see what Arbutus Biopharma Corp (ABUS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 97.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.43, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.34 in one year’s time.
Technical Analysis of Arbutus Biopharma Corp (ABUS)
Analysing the last 5-days average volume posted by the [Arbutus Biopharma Corp, ABUS], we can find that recorded value of 1.11 million was better than the volume posted last year of 1.11 million. As of the previous 9 days, the stock’s Stochastic %D was 11.70%. Additionally, its Average True Range was 0.15.
During the past 100 days, Arbutus Biopharma Corp’s (ABUS) raw stochastic average was set at 17.92%, which indicates a significant increase from 1.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 26.19% in the past 14 days, which was lower than the 38.89% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.86, while its 200-day Moving Average is $3.39. Now, the first resistance to watch is $3.53. This is followed by the second major resistance level at $3.64. The third major resistance level sits at $3.70. If the price goes on to break the first support level at $3.36, it is likely to go to the next support level at $3.30. Should the price break the second support level, the third support level stands at $3.19.
Arbutus Biopharma Corp (NASDAQ: ABUS) Key Stats
There are 189,492K outstanding shares of the company, which has a market capitalization of 657.43 million. As of now, sales total 18,140 K while income totals -72,850 K. Its latest quarter income was 1,340 K while its last quarter net income were -19,720 K.
